← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in urothelial carcinoma: P43363

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
November 19, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P43363 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in urothelial carcinoma.

Background

P43363 is a putative protein target identified in urothelial carcinoma, a malignancy of the urinary tract with significant clinical challenges. Preliminary expression profiling data suggest that P43363 may be differentially expressed in urothelial carcinoma tissues compared to normal urothelium. Although its precise biological role in urothelial carcinoma is not yet defined, the expression pattern of P43363 indicates potential involvement in tumor biology, positioning it as a candidate for further experimental validation.

Data-mining rationale

This candidate was identified by cross-referencing UniProt’s reviewed human protein entries annotated for "urothelial carcinoma" against 74 microarray datasets from the NCBI Gene Expression Omnibus (GEO). Several datasets relevant to urothelial carcinoma (GDS:200292216, GDS:200245118, GDS:200253531, GDS:200201395, GDS:200181962) showed expression signals for P43363. Notably, no Phase 1 or later clinical trials targeting P43363 were detected in the current clinical program landscape, suggesting it remains an underexplored target in urothelial carcinoma.

Why prior analyses may have missed this

Many of the GEO datasets analyzed predate the adoption of modern empirical-Bayes statistical methods such as limma, which improve the detection of differentially expressed genes by enhancing statistical power and controlling for false discovery rates. Earlier analyses may have relied on less rigorous statistical approaches without proper multiple-testing correction, increasing the likelihood of false negatives and potentially overlooking relevant targets like P43363. Re-analysis of these datasets using contemporary bioinformatics pipelines could uncover stronger evidence supporting P43363’s differential expression and relevance in urothelial carcinoma.

Reasoning for further validation

To clarify the putative role of P43363 in urothelial carcinoma and assess its potential as a therapeutic target, the following experimental steps are recommended:

  1. Re-analysis of GEO datasets: Apply limma with Benjamini-Hochberg false discovery rate correction (FDR < 0.05) to confirm differential expression of P43363 in urothelial carcinoma versus normal tissue.
  1. Independent cohort validation: Validate P43363 expression by quantitative PCR (qPCR) in an independent set of urothelial carcinoma and matched normal tissue specimens.
  1. Tissue specificity profiling: Assess P43363 expression across normal tissues using resources such as GTEx and the Human Protein Atlas to evaluate baseline tissue distribution and potential off-target effects.
  1. Pathway and interaction analysis: Use protein interaction databases like STRING and OmniPath to place P43363 within molecular pathways relevant to urothelial carcinoma biology.
  1. Druggability assessment: If validated, investigate druggability of P43363 through databases such as DGIdb and ChEMBL to identify potential modulators.

These investigations will provide a structured framework to validate P43363 as a putative target in urothelial carcinoma and guide subsequent preclinical research.


© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications